Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Failure to Monitor for Adverse Effects of Anticoagulant Medication

Sardis, Mississippi Survey Completed on 07-01-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to monitor for adverse effects of an anticoagulant medication for one resident who was prescribed Apixaban for acute embolism and thrombosis of the femoral vein. Review of the resident's physician orders, medication administration record, and treatment administration record revealed that there was no monitoring protocol in place to observe for side effects associated with anticoagulant therapy, such as bleeding or excessive bruising. The facility's policy required observation for adverse effects and physician notification if any occurred, but this was not implemented for the resident in question. Interviews with staff, including an LPN, the MDS Coordinator, and the DON, confirmed that there were no specific orders or monitoring tasks in place to assess for bleeding risks related to the anticoagulant medication. Staff emphasized the importance of such monitoring and acknowledged its absence, noting that monitoring should begin whenever an anticoagulant is prescribed. The resident involved was cognitively intact and had been admitted with a diagnosis of acute embolism and thrombosis.

An unhandled error has occurred. Reload 🗙